Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability,feasibility, and efficacy of combining acalabrutinib with RICE
chemotherapy as second line therapy in relapsed/refractory DLBCL patients with separate
primary objectives in each of in two cohorts:
Cohort A: Hematopoeitic stem cell transplantation (HSCT) eligible patients undergoing
second-line salvage chemoimmunotherapy [Rituximab, Ifosfamide, Carboplatin, and Etoposide
(RICE)] plus acalabrutinib:.
Cohort B: Individuals not eligible for HSCT undergoing second-line salvage chemoimmunotherapy
[Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE)] plus acalabrutinib followed by
acalabrutinib as a maintenance therapy